Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment

Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment

Abstract Background It has previously been shown that bevacizumab, when added to chemotherapy, improved overall survival in several cancers. In glioblastoma multiforme (GBM), bevacizumab increased progression-free survival and it is widely used for tumor recurrence, though it has failed to improve o...

Full description

Bibliographic Details
Main Authors: Chiung-Chyi Shen, Wen-Yu Cheng, Chung-Hsin Lee, Xue-Jun Dai, Ming-Tsang Chiao, Yea-Jiuen Liang, Wan-Yu Hsieh, Tsuo-Fei Mao, Guo-Shi Lin, Shou-Ren Chen, Bai-Shuan Liu, Jun-Peng Chen
Format: Article
Language:English
Published: BMC 2020-07-01
Series:BMC Cancer
Subjects:
Glioblastoma multiforme
Polymorphism
p53
Codon 72
Bevacizumab
SNP
Online Access:http://link.springer.com/article/10.1186/s12885-020-07210-8

Internet

http://link.springer.com/article/10.1186/s12885-020-07210-8

Similar Items